MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV

PHASE4TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

October 22, 2018

Study Completion Date

October 22, 2018

Conditions
Hepatitis C, Chronic
Interventions
DRUG

OBV/PTV/r and DSV

OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.

DRUG

Placebo to match OBV/PTV/r and DSV

Placebo to match OBV/PTV/r and DSV

Trial Locations (1)

30625

Hannover Medical School, Hanover

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Hannover Medical School

OTHER